Open an account

ALX Oncology Holdings

ALXO · NASDAQ

$1.24+$0.10 (+8.77%)TodayMarket closed ·
Prev close $1.14

About ALXO

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 43 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.

Employees
43
Headquarters
South San Francisco, California
Listed
Jul 17, 2020
Sector
Health Care
Industry
Biotechnology
Website
alxoncology.com

ALXO key statistics

Market cap
171.46M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.51M
Volume
871.52K
Open price
$1.13
High today
$1.27
Low today
$1.11
52 Week high
$2.66
52 Week low
$0.8617

ALX Oncology Holdings (ALXO) at a glance

As of Oct 20, 2026, ALX Oncology Holdings (ALXO) shares are priced at $1.24, giving the company a market cap of 171.46M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.11 and $1.27. The current price is 11.7% above the day's low and 2.4% below its high.

Volume so far is 871.52K shares, below the average of 1.51M shares a day.

Over the past year ALX Oncology Holdings has ranged from $0.8617 to $2.66, and now sits 21% of the way up that range.

ALX Oncology Holdings met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.12 per share against an estimate of -$0.1462.

The average analyst price target is $4.69, 278.4% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $4.69
Low
$4.04
Now
$1.24
High
$6.30

ALXO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 19.4% on average.

  1. Q3 FY24: reported -$0.58 per share against an estimate of -$0.7956
  2. Q4 FY24: reported -$0.55 per share against an estimate of -$0.6834
  3. Q1 FY25: reported -$0.58 per share against an estimate of -$0.4733
  4. Q2 FY25: reported -$0.43 per share against an estimate of -$0.459
  5. Q3 FY25: reported -$0.41 per share against an estimate of -$0.374
  6. Q4 FY25: reported -$0.37 per share against an estimate of -$0.3697
  7. Q1 FY26: reported -$0.146 per share against an estimate of -$0.1979
  8. Q2 FY26: reported -$0.12 per share against an estimate of -$0.1462

ALXO news

  • Press releaseGlobe Newswire

    ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Press releaseGlobe Newswire

    ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

  • Press releaseGlobe Newswire

    ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

  • A Look Ahead: ALX Oncology Holdings's Earnings Forecast

  • Press releaseGlobe Newswire

    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

  • Press releaseGlobe Newswire

    ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

  • Examining the Future: ALX Oncology Holdings's Earnings Outlook

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as ALX Oncology Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.